Table 2. Summary of finding table for HCC patients with tumor less than 5.
| Event,% | Effect estimate# | Illustrative comparative risks(95%CI)Ψ | |||||||||
| Indicators | Years | No. of Participants (studies) | RFA | HR | OR,95% CI | I2 (%) | P value | NNT or NNH | Assumed risk HR(control)(per 1000) | Corresponding risk RFA(per 1000) | Quality of evidence (GRADE) |
| Overall survival | 1-y | 559(3) | 92.2 | 95.2 | 0.98[0.89,1.09] | 83 | 0.71 | 33.3† | 933 | 914 (830 to 1000) | ⊕⊕⊕⊖ Moderate |
| 3-y | 559(3) | 74.4 | 78.9 | 0.98[0.74,1.29] | 89 | 0.87 | 22.2† | 733 | 718 (542 to 946) | ⊕⊕⊕⊖ Moderate | |
| 5-y | 230(1) | 54.8 | 75.7 | 0.72[0.60,0.88] | — | — | 4.8† | 757 | 545 (454 to 666) | ⊕⊕⊕⊕High | |
| Recurrence-free survival | 1-y | 398(2) | 85.4 | 85.4 | 1.01[0.92,1.11] | 29 | 0.88 | _ | 855 | 864 (787 to 949) | ⊕⊕⊕⊕High |
| 3-y | 398(2) | 52.3 | 56.3 | 0.95[0.60,1.52] | 84 | 0.85 | 25.0† | 554 | 526 (332 to 842) | ⊕⊕⊕⊖ Moderate | |
| 5-y | 230(1) | 28.7 | 51.3 | 0.56[0.40,0.78] | — | — | 4.4† | 513 | 287 (205 to 400) | ⊕⊕⊕⊕High | |
| Disease-free survival | 1-y | 180(1) | 91.1 | 86.7 | 1.05[0.95,1.17]& | — | 0.34 | 22.7‡ | 867 | 910 (824 to 1000) | ⊕⊕⊕⊖Moderate |
| 2-y | 180(1) | 68.9 | 76.7 | 0.90[0.75,1.08]& | — | 0.24 | 12.8† | 767 | 690 (575 to 828) | ⊕⊕⊕⊖Moderate | |
| 3-y | 180(1) | 60.0 | 68.9 | 0.87[0.70,1.08]& | — | 0.22 | 11.2† | 689 | 599 (482 to 744) | ⊕⊕⊕⊖Moderate | |
| 4-y | 180(1) | 47.8 | 51.1 | 0.93[0.70,1.26]& | — | 0.65 | 30.3† | 511 | 475 (358 to 644) | ⊕⊕⊕⊖Moderate | |
| Recurrence | 1-y | 398(2) | 15.6 | 11.1 | 1.41[0.85,2.35]& | 0 | 0.19 | 22.2† | 109 | 154 (93 to 256) | ⊕⊕⊕⊖ Moderate |
| 3-y | 398(2) | 43.2 | 29.1 | 1.48[1.14,1.94]& | 0 | 0.004* | 7.1† | 304 | 450 (347 to 590) | ⊕⊕⊕⊖ Moderate | |
| 5-y | 230(1) | 63.5 | 41.7 | 1.52[1.18,1.97]& | — | 0.001* | 4.6† | 417 | 634 (492 to 821) | ⊕⊕⊕⊖ Moderate | |
| Local recurrence | 398(2) | 20.6 | 14.1 | 1.46[0.97,2.21]& | 0 | 0.07 | 15.4† | 159 | 232 (154 to 351) | ⊕⊕⊕⊖ Moderate | |
| Distant recurrence | 398(2) | 5.0 | 4.0 | 1.25[0.50,3.10]& | 0 | 0.63 | 100.0† | 40 | 50 (20 to 124) | ⊕⊕⊕⊖ Moderate | |
| In-hospital Mortality | 559(3) | 0.0 | 0.3 | 0.42[0.02,10.19]& | — | 0.59 | 333.3‡ | 0 | 0 (0 to 0) | ⊕⊕⊕⊖ Moderate | |
| Complication rate | 559(3) | 5.9 | 34.6 | 0.18[0.06,0.53] | 74 | 0.002* | 3.5‡ | 278 | 50 (17 to 147) | ⊕⊕⊕⊖ Moderate | |
| Hospital stay | 559(3) | — | — | -8.77[−10.36,−7.18]△ | 83 | <0.001* | _ | _ | RFA group was 8.77 lower(10.36 to 7.18 lower) | ⊕⊕⊕⊖ Moderate | |
Ψ: The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI);
#, random-effect model;
&, fixed-effect model;
△: Mean Difference (IV, Random, 95% CI).
,NNH(Number needed to harm);
‡,NNT(Number needed to treat);
*:p<0.05